Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs ATACAND HCT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Hypertension,Edema associated with congestive heart failure, cirrhosis, or nephrotic syndrome,Hypokalemia prevention or correction in patients on diuretics
Treatment of hypertension, for patients not adequately controlled on monotherapy.
One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
Amiloride: 6-9 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment, heart failure).
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Amiloride is not metabolized; excreted unchanged in urine. Hydrochlorothiazide is not extensively metabolized; small amounts are metabolized hepatically via CYP450 enzymes, but the exact pathways are not well defined.
Candesartan is primarily metabolized by hepatic O-deethylation via CYP2C9 to an inactive metabolite. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged by the kidneys.
Amiloride: 50% unchanged in urine, 40% in feces (biliary); Hydrochlorothiazide: >95% unchanged in urine.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Amiloride: ~23%; Hydrochlorothiazide: 40-68% (primarily to albumin).
Candesartan: >99% (primarily albumin). Hydrochlorothiazide: 40-70% (primarily albumin).
Amiloride: 350-440 L (5-6 L/kg in 70 kg adult), indicating extensive tissue distribution; Hydrochlorothiazide: 3-5 L/kg, distributes into extracellular space.
Candesartan: 0.13 L/kg (extensive tissue distribution). Hydrochlorothiazide: 0.83-2.5 L/kg (distributes into plasma and red blood cells).
Amiloride: 50-80% (oral); Hydrochlorothiazide: 60-80% (oral).
Candesartan: ~15% (absolute, prodrug conversion). Hydrochlorothiazide: ~70% (oral).
Contraindicated if GFR <30 m L/min or serum creatinine >2.5 mg/d L. For GFR 30-50 m L/min: use with caution and monitor electrolytes; avoid if further renal impairment.
Contraindicated if GFR <30 m L/min/1.73 m2. No adjustment for GFR 30-50 m L/min/1.73 m2. Use with caution and monitor renal function.
Child-Pugh Class A: no adjustment; Class B: reduce dose or use alternative; Class C: avoid use (risk of hepatic encephalopathy).
Mild to moderate hepatic impairment (Child-Pugh A or B): No dose adjustment. Severe impairment (Child-Pugh C): Not recommended due to hydrochlorothiazide accumulation risk.
Not established; safety and efficacy not determined in children.
Safety and efficacy not established in pediatric patients (<18 years).
Start at lowest dose, monitor electrolytes and renal function; increased sensitivity to hypotension and electrolyte disturbances; avoid if creatinine clearance <30 m L/min.
No initial dose adjustment required. Use caution due to increased sensitivity to hypotension and electrolyte disturbances; monitor renal function and electrolytes.
None
None.
Hyperkalemia risk, especially with renal impairment, diabetes, or concomitant use of potassium supplements, ACE inhibitors, or aldosterone antagonists,Electrolyte imbalances (hyponatremia, hypomagnesemia, hypochloremia),Azotemia and renal impairment,Sulfonamide hypersensitivity cross-reactivity (hydrochlorothiazide is a sulfonamide derivative),Acute angle-closure glaucoma (rare with thiazides),Monitor serum electrolytes, renal function, and blood glucose
Fetal toxicity: Use in pregnancy can cause oligohydramnios, fetal renal dysfunction, and skull ossification defects. Discontinue as soon as possible when pregnancy is detected.,Hypotension: Symptomatic hypotension may occur in volume-depleted patients. Correct volume depletion before initiation.,Impaired renal function: Monitor renal function due to risk of acute renal failure, especially in patients with renal artery stenosis.,Electrolyte imbalances: Hydrochlorothiazide can cause hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia; candesartan can cause hyperkalemia.,Metabolic effects: Thiazides may increase serum cholesterol, triglycerides, and uric acid levels; may cause hyperglycemia.,Acute angle-closure glaucoma: Hydrochlorothiazide can cause acute transient myopia and acute angle-closure glaucoma.,Systemic lupus erythematosus: Thiazides have been reported to cause exacerbation or activation of SLE.,Non-melanoma skin cancer: Thiazide diuretics may increase risk; monitor for skin lesions.
Anuria,Acute or chronic renal insufficiency (creatinine clearance <10 m L/min),Hyperkalemia (serum potassium >5.5 m Eq/L),Concomitant use of other potassium-sparing diuretics, potassium supplements, or amiloride-containing drugs,Hypersensitivity to amiloride, hydrochlorothiazide, or sulfonamide-derived drugs
Hypersensitivity to candesartan, hydrochlorothiazide, or any component of the formulation.,Anuria (hydrochlorothiazide component).,Pregnancy (second and third trimesters).,Severe renal impairment (Cr Cl <30 m L/min).,Concomitant use with aliskiren in patients with diabetes mellitus.
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) in large amounts. Limit salt intake. Grapefruit juice may increase hydrochlorothiazide absorption; avoid concurrent consumption.
Avoid salt substitutes containing potassium chloride unless approved by your doctor. Limit high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia risk is present. Take hydrochlorothiazide with food or milk to reduce gastrointestinal upset. Grapefruit juice has no significant interaction with this combination.
First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence is inconclusive. Second and third trimesters: Hydrochlorothiazide may cause fetal/neonatal electrolyte disturbances, jaundice, and thrombocytopenia. Amiloride has not been associated with major teratogenic effects in animal studies, but human data are inadequate. Overall risk is moderate; avoid in pregnancy if possible, especially for treatment of hypertension, as alternatives exist.
Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal renal failure. Angiotensin receptor blocker (ARB) component: similar adverse effects. Thiazide diuretic: risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use contraindicated in pregnancy.
Hydrochlorothiazide is excreted into breast milk in low amounts (M/P ratio approximately 1.5); amiloride is also excreted in animal milk but human data lacking. Potential for neonatal electrolyte imbalance and thrombocytopenia from thiazide. Use during breastfeeding is not recommended unless essential. Monitor infant for signs of dehydration and electrolyte disturbances.
Candesartan (ARB) and hydrochlorothiazide (HCTZ) are excreted in breast milk. M/P ratio not established for candesartan; HCTZ M/P ratio is approximately 0.6. HCTZ may suppress lactation. Use not recommended during breastfeeding due to potential adverse effects in the infant, including electrolyte imbalance, hypotension, and renal impairment.
No specific dose adjustments recommended for pregnancy due to lack of pharmacokinetic studies; however, increased renal clearance during pregnancy may reduce diuretic efficacy. Caution with hypovolemia and electrolyte disturbances. Use lowest effective dose and consider alternative agents for hypertension in pregnancy (e.g., methyldopa, labetalol).
Dose adjustments not applicable; drug is contraindicated in pregnancy. If unintentionally exposed, discontinue as soon as pregnancy is detected. No dose adjustment recommendations for pregnancy due to lack of safe use data.
Amiloride is potassium-sparing; hydrochlorothiazide causes potassium loss. The combination offsets hypokalemia risk. Monitor serum potassium, especially in renal impairment or with NSAIDs. Avoid in anuria or severe renal disease. Onset of diuresis: 2 hours; peak effect: 6-12 hours; duration: 24 hours.
ATACAND HCT is a fixed-dose combination of candesartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor renal function and electrolytes, especially potassium and sodium, within 2 weeks of initiation and periodically thereafter. Avoid use in pregnancy; discontinue as soon as pregnancy is detected. May cause symptomatic hypotension, particularly in volume-depleted patients; correct volume depletion before starting. Can exacerbate gout due to thiazide-induced hyperuricemia. Not recommended for use with aliskiren in patients with diabetes or renal impairment (GFR <60 m L/min).
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug increases urine output and may cause dizziness or lightheadedness; rise slowly from sitting or lying down.,Avoid potassium supplements or salt substitutes containing potassium unless directed by your doctor.,Limit alcohol intake as it can increase dizziness and orthostatic hypotension.,Notify your doctor if you experience muscle cramps, weakness, irregular heartbeat, or excessive thirst.
Do not take if you are pregnant, plan to become pregnant, or are breastfeeding.,Take exactly as prescribed; do not skip doses or double up.,Drink adequate fluids to prevent dehydration unless instructed otherwise by your doctor.,Avoid alcohol and NSAIDs (e.g., ibuprofen) as they may increase side effects.,Report symptoms like lightheadedness, excessive thirst, muscle cramps, or irregular heartbeat.,Monitor blood pressure regularly at home and keep a log.,This medication may increase sensitivity to sunlight; use sunscreen and protective clothing.
"The coadministration of Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), with Chlorothiazide, a thiazide diuretic, may result in a diminished antihypertensive and diuretic effect of Chlorothiazide. Sulindac can inhibit renal prostaglandin synthesis, leading to sodium and water retention, which counteracts the natriuretic and hypotensive actions of Chlorothiazide. This interaction may result in reduced blood pressure control and potentially exacerbate edema in patients with hypertension or heart failure."
"Concomitant use of torasemide, a loop diuretic, and chlorothiazide, a thiazide diuretic, produces synergistic blockade of sodium reabsorption along the nephron, leading to profound diuresis, electrolyte disturbances, and volume depletion. This combination increases the risk of severe hypokalemia, hyponatremia, hypomagnesemia, and metabolic alkalosis, potentially precipitating cardiac arrhythmias, hypotension, or renal impairment, especially in patients with compromised renal function or those on digoxin or antiarrhythmics."
"Flurandrenolide, a topical corticosteroid, can be absorbed systemically and enhance the hypokalemic effect of chlorothiazide, a thiazide diuretic. This interaction occurs through additive potassium-wasting actions: flurandrenolide promotes renal potassium excretion via mineralocorticoid-like effects, while chlorothiazide increases distal tubular potassium loss. Clinically, this can lead to severe hypokalemia, potentially causing cardiac arrhythmias, muscle weakness, and impaired glucose tolerance."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs ATACAND HCT, answered by our medical review team.
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is a Thiazide Diuretic that works by Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENa C) in the distal convoluted tubule and collecting duct, inhibiting sodium reabsorption and reducing potassium excretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, increasing sodium, chloride, and water excretion.. ATACAND HCT is a Angiotensin II Receptor Blocker / Thiazide Diuretic that works by ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE and ATACAND HCT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is: One tablet (amiloride 5 mg/hydrochlorothiazide 50 mg) orally once daily initially, increased if needed to twice daily. Maximum dose: amiloride 10 mg/hydrochlorothiazide 100 mg daily.. The standard adult dose of ATACAND HCT is: One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE and ATACAND HCT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is classified as Category A/B. First trimester: Limited data; thiazide use associated with possible increased risk of congenital anomalies including neural tube defects and limb reduction defects, but evidence i. ATACAND HCT is classified as Category C. Pregnancy Category D. First trimester: potential fetotoxicity; second and third trimesters: ACE inhibitor exposure causes oligohydramnios, fetal renal dysfunction, skull ossificati. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.